Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - guidance (TA473)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
31 August 2017

Abstract

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults.

This guidance is a Cancer Drugs Fund reconsideration of cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172). This guidance replaces TA172.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: August 2020